Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel.

Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson SF, Miller PJ, Somer BG.

J Community Support Oncol. 2014 Sep;12(9):321-8. doi: 10.12788/jcso.0072.

PMID:
25848909
2.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K, Le N.

Eur J Cancer. 2014 Aug;50(12):2072-81. doi: 10.1016/j.ejca.2014.04.024. Epub 2014 Jun 7.

PMID:
24915778
3.

Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Schwartzberg LS, Wang G, Somer BG, Blakely LJ, Wheeler BM, Walker MS, Stepanski EJ, Houts AC.

Clin Breast Cancer. 2014 Feb;14(1):13-9. doi: 10.1016/j.clbc.2013.09.003. Epub 2013 Sep 27.

PMID:
24268206
4.

A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.

Wiechno P, Somer BG, Mellado B, Chłosta PL, Cervera Grau JM, Castellano D, Reuter C, Stöckle M, Kamradt J, Pikiel J, Durán I, Wedel S, Callies S, André V, Hurt K, Brown J, Lahn M, Heinrich B.

Eur Urol. 2014 Mar;65(3):516-20. doi: 10.1016/j.eururo.2013.10.039. Epub 2013 Nov 6.

PMID:
24246407
5.

Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.

Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ; American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines.

Arthritis Rheum. 2003 Jun 15;49(3):394-8. No abstract available.

6.

Natriuretic peptides and their therapeutic potential.

Cho Y, Somer BG, Amatya A.

Heart Dis. 1999 Nov-Dec;1(5):305-28. Review.

PMID:
11720638
7.

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA.

Transplantation. 2001 Apr 27;71(8):1076-88.

PMID:
11374406
8.

Atrial natriuretic peptide and its potential role in pharmacotherapy.

Deutsch A, Frishman WH, Sukenik D, Somer BG, Youssri A.

J Clin Pharmacol. 1994 Dec;34(12):1133-47. Review.

PMID:
7738207

Supplemental Content

Loading ...
Support Center